These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32469893)

  • 1. Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
    Mpendo J; Mutua G; Nanvubya A; Anzala O; Nyombayire J; Karita E; Dally L; Hannaman D; Price M; Fast PE; Priddy F; Gelderblom HC; Hills NK
    PLoS One; 2020; 15(5):e0233151. PubMed ID: 32469893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
    Elizaga ML; Li SS; Kochar NK; Wilson GJ; Allen MA; Tieu HVN; Frank I; Sobieszczyk ME; Cohen KW; Sanchez B; Latham TE; Clarke DK; Egan MA; Eldridge JH; Hannaman D; Xu R; Ota-Setlik A; McElrath MJ; Hay CM;
    PLoS One; 2018; 13(9):e0202753. PubMed ID: 30235286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
    Vasan S; Hurley A; Schlesinger SJ; Hannaman D; Gardiner DF; Dugin DP; Boente-Carrera M; Vittorino R; Caskey M; Andersen J; Huang Y; Cox JH; Tarragona-Fiol T; Gill DK; Cheeseman H; Clark L; Dally L; Smith C; Schmidt C; Park HH; Kopycinski JT; Gilmour J; Fast P; Bernard R; Ho DD
    PLoS One; 2011; 6(5):e19252. PubMed ID: 21603651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety and Immunogenicity of GTU
    Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
    Front Immunol; 2019; 10():2911. PubMed ID: 31921170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
    Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP
    Edupuganti S; C De Rosa S; Elizaga M; Lu Y; Han X; Huang Y; Swann E; Polakowski L; A Kalams S; Keefer M; Maenza J; C Wise M; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Sardesai NY; Bagarazzi ML; Gilbert PB; Kublin JG; Corey L; Weiner DB; On Behalf Of The Hvtn Study Team ; The Niaid-Funded Hiv Vaccine Trials Network
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33297341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
    Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
    Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
    Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V
    Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Spearman P; Mulligan M; Anderson EJ; Shane AL; Stephens K; Gibson T; Hartwell B; Hannaman D; Watson NL; Singh K
    Vaccine; 2016 Nov; 34(46):5571-5578. PubMed ID: 27697302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.
    Jiang J; Ramos SJ; Bangalore P; Fisher P; Germar K; Lee BK; Williamson D; Kemme A; Schade E; McCoy J; Muthumani K; Weiner DB; Humeau LM; Broderick KE
    Vaccine; 2019 Jun; 37(29):3832-3839. PubMed ID: 31174938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs.
    Sheng Z; Gao N; Cui X; Fan D; Chen H; Wu N; Wei J; An J
    Vaccine; 2016 Nov; 34(47):5751-5757. PubMed ID: 27743649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.